ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections

Clinical Microbiology and Infection

Volumn 20, Issue S3, 2014, Pages 76-98

  Arendrup, M C ^a   Boekhout, T ^b,c,d   Akova, M ^e   Meis, J F ^f,g   Cornely, O A ^h   Lortholary, O ^i,j   Arikan Akdagli, Sevtap ^e   Cuenca Estrella, Manuel ^k   Dannaoui, Eric ^l   van Diepeningen, Anne D ^m   Groll, Andreas H ⁿ   Guarro, Josep ^o   Guinea, Jesús ^p   Hope, William ^q   Lackner, Michaela ^r   Lass Flörl, Cornelia ^r   Lagrou, Katrien ^s   Lanternier, Fanny ^i,t   Meletiadis, Joseph ^u   Munoz, Patricia ^p   Pagano, Livio ^v   Richardson, Malcolm D ^w   Roilides, Emmanuel ^x   Tortorano, Anna Maria ^y   Ullmann, Andrew J ^z   more..

^a STATENS SERUM INSTITUT   (Denmark)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

^e HACETTEPE UNIVERSITY   (Turkey)

^f CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY OF COLOGNE   (Germany)

ⁱ INSTITUT PASTEUR   (France)

^j HÔPITAL NECKER ENFANTS MALADES   (France)

^k INSTITUTO DE SALUD CARLOS III   (Spain)

^l HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^m CBS KNAW FUNGAL BIODIVERSITY CENTRE   (Netherlands)

ⁿ UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^o UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^p HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^q UNIVERSITY OF LIVERPOOL   (United Kingdom)

^r INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^s Department of Microbiology and Immunology Clinical Department of Laboratory Medicine   (Belgium)

^t UNIVERSITÉ PARIS DESCARTES   (France)

^u NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^v CATHOLIC UNIVERSITY   (Italy)

^w MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^x ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^y UNIVERSITY OF MILAN   (Italy)

^z UNIVERSITY OF WÜRZBURG   (Germany)

more..

Author keywords

Clinical guideline; Cryptococcus; Geotrichum; Kodamaea; Malassezia; Pseudozyma; Rhodotorula; Saccharomyces; Saprochaete; Sporobolomyces; Trichosporon

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; PROBIOTIC AGENT; PYRROLE DERIVATIVE; TERBINAFINE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CRYPTOCOCCUS ADELIENSIS; CRYPTOCOCCUS ALBIDUS; CRYPTOCOCCUS CURVATUS; CRYPTOCOCCUS FLAVESCENS; CRYPTOCOCCUS LAURENTII; CRYPTOCOCCUS UNIGUTTULATUS; DIAGNOSTIC TEST; DISEASE PREDISPOSITION; FUNGAL DETECTION; GALACTOMYCES GEOTRICHUM; GEOTRICHUM; HEMATOLOGIC MALIGNANCY; HOSPITAL INFECTION; HUMAN; KODAMAEA OHMERI; MALASSEZIA; MALASSEZIA FURFUR; MALASSEZIA GLOBOSA; MALASSEZIA PACHYDERMATIS; MALASSEZIA RESTRICTA; MEDICAL SOCIETY; MINIMUM INHIBITORY CONCENTRATION; NEUTROPENIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSEUDOZYMA; RARE DISEASE; RHODOTORULA GLUTINIS; RHODOTORULA MINUTA; RHODOTORULA MUCILAGINOSA; RISK FACTOR; SACCHAROMYCES CEREVISIAE; SAPROCHAETE CAPITATAE; SAPROCHAETE CLAVATA; SKIN FLORA; SPOROBOLOMYCES; SYSTEMIC MYCOSIS; THERAPY DELAY; TRICHOSPORON ASAHII; TRICHOSPORON ASTEROIDES; TRICHOSPORON CAPITATUM; TRICHOSPORON DERMATIS; TRICHOSPORON INKIN; TRICHOSPORON JIROVECII; TRICHOSPORON LOUBIERI; TRICHOSPORON MUCOIDES; TRICHOSPORON MYCOTOXINIVORANS; YEAST;

CLINICAL GUIDELINE; CRYPTOCOCCUS; GEOTRICHUM; KODAMAEA; MALASSEZIA; PSEUDOZYMA; RHODOTORULA; SACCHAROMYCES; SAPROCHAETE; SPOROBOLOMYCES; TRICHOSPORON;

HUMANS; MYCOSES; RARE DISEASES;

EID: 84895813342     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12360     Document Type: Article

References (273)

1. Ullmann AJ, Cornely OA, Donnelly JP et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases. Clin Microbiol Infect 2012; 18: 1-8.
2. Cuenca-Estrella M, Verweij PE, Arendrup MC et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect 2012; 18: 9-18.
3. Cornely OA, Bassetti M, Calandra T et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 2012; 18: 19-37.
4. Hope WW, Castagnola E, Groll AH et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect 2012; 18: 38-52.
5. Ullmann AJ, Akova M, Herbrecht R et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect 2012; 18: 53-67.
6. Lortholary O, Petrikkos G, Akova M et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS. Clin Microbiol Infect 2012; 18: 68-77.
7. Borman AM, Szekely A, Linton CJ, Palmer MD, Brown P, Johnson EM. Epidemiology, antifungal susceptibility, and pathogenicity of Candida africana isolates from the United Kingdom. J Clin Microbiol 2013; 51: 967-972.
8. Lee WG, Shin JH, Uh Y et al. First three reported cases of nosocomial fungemia caused by Candida auris. J Clin Microbiol 2011; 49: 3139-3142.
9. Mirhendi H, Bruun B, Schonheyder HC et al. Differentiation of Candida glabrata, C. nivariensis and C. bracarensis based on fragment length polymorphism of ITS1 and ITS2 and restriction fragment length polymorphism of ITS and D1/D2 regions in rDNA. Eur J Clin Microbiol Infect Dis 2011; 30: 1409-1416.
10. Agin H, Ayhan Y, Devrim I, Gulfidan G, Tulumoglu S, Kayserili E. Fluconazole-, amphotericin-B-, caspofungin-, and anidulafungin-resistant Candida ciferrii: an unknown cause of systemic mycosis in a child. Mycopathologia 2011; 172: 237-239.
11. Sullivan DJ, Moran GP, Pinjon E et al. Comparison of the epidemiology, drug resistance mechanisms, and virulence of Candida dubliniensis and Candida albicans. FEMS Yeast Res 2004; 4: 369-376.
12. Bhally HS, Jain S, Shields C, Halsey N, Cristofalo E, Merz WG. Infection in a neonate caused by Pichia fabianii: importance of molecular identification. Med Mycol 2006; 44: 185-187.
13. Jensen RH, Arendrup MC. Candida palmioleophila: characterisation of a previously overlooked pathogen and its unique susceptibility profile in comparison with five related species. J Clin Microbiol 2011; 49: 549-556.
14. Cendejas-Bueno E, Kolecka A, Alastruey-Izquierdo A et al. Reclassification of the Candida haemulonii complex as Candida haemulonii (C. haemulonii group I), C. duobushaemulonii sp. nov. (C. haemulonii group II), and C. haemulonii var. vulnera var. nov.: three multiresistant human pathogenic yeasts. J Clin Microbiol 2012; 50: 3641-3651.
15. Brandt ME, Kauffman CA, Pappas PG et al. Fungemia caused by Zygoascus hellenicus in an allogeneic stem cell transplant recipient. J Clin Microbiol 2004; 42: 3363-3365.
16. Sugita T, Takeo K, Ohkusu M et al. Fluconazole-resistant pathogens Candida inconspicua and C. norvegensis: DNA sequence diversity of the rRNA intergenic spacer region, antifungal drug susceptibility, and extracellular enzyme production. Microbiol Immunol 2004; 48: 761-766.
17. Atkinson BJ, Lewis RE, Kontoyiannis DP. Candida lusitaniae fungemia in cancer patients: risk factors for amphotericin B failure and outcome. Med Mycol 2008; 46: 541-546.
18. Mirhendi H, Bruun B, Schonheyder HC et al. Molecular screening for Candida orthopsilosis and Candida metapsilosis among Danish Candida parapsilosis group blood culture isolates: proposal of a new RFLP profile for differentiation. J Med Microbiol 2010; 59: 414-420.
19. Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ, Jones RN. In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. J Clin Microbiol 2003; 41: 78-83.
20. Taylor JW. One Fungus = One Name: DNA and fungal nomenclature twenty years after PCR. IMA Fungus 2011; 2: 113-120.
21. Barnett JA, Payne RW, Yarrow D. Yeasts: characteristics and identification, 3rd edn. Cambridge: Cambridge University Press, 2007.
22. Gupta AK, Ryder JE, Nicol K, Cooper EA. Superficial fungal infections: an update on pityriasis versicolor, seborrheic dermatitis, tinea capitis, and onychomycosis. Clin Dermatol 2003; 21: 417-425.
23. Hu SW, Bigby M. Pityriasis versicolor: a systematic review of interventions. Arch Dermatol 2010; 146: 1132-1140.
24. Khandpur S, Reddy BS. Itraconazole therapy for white piedra affecting scalp hair. J Am Acad Dermatol 2002; 47: 415-418.
25. Bonifaz A, Gomez-Daza F, Paredes V, Ponce RM. Tinea versicolor, tinea nigra, white piedra, and black piedra. Clin Dermatol 2010; 28: 140-145.
26. Arendrup MC, Bruun B, Christensen JJ et al. National surveillance of fungemia in Denmark 2004-2009. J Clin Microbiol 2011; 49: 325-334.
27. Arendrup MC, Dzajic E, Jensen RH et al. Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme. Clin Microbiol Infect 2013; 19: E343-E353.
28. Chitasombat MN, Kofteridis DP, Jiang Y, Tarrand J, Lewis RE, Kontoyiannis DP. Rare opportunistic (non-Candida, non-Cryptococcus) yeast bloodstream infections in patients with cancer. J Infect 2012; 64: 68-75.
29. Pfaller MA, Diekema DJ, Gibbs DL et al. Results from the ARTEMIS DISK global antifungal surveillance study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2009; 47: 117-123.
30. Duboc De Almeida GM, Figueiredo Costa S, Melhem M et al. Rhodotorula spp. isolated from blood cultures: clinical and microbiological aspects. Med Mycol 2008; 46: 547-556.
31. Kurtzman CP. Discussion of teleomorphic and anamorphic ascomycetous yeasts and yeast-like taxa. In: Kurtzman CP, Fell JW, Boekhout T, eds. The yeasts, a taxonomic study, 5th edn. Amsterdam: Elsevier, 2011; 293-307.
32. Baron EJ, Weinstein MP, Dunne WM, Yagupsky P, Welsh DF, Wilson DM. Cumitech 1C, blood cultures IV. Washington, DC: ASM Press, 2005.
33. Arendrup MC, Bille J, Dannaoui E, Ruhnke M, Heussel CP, Kibbler C. ECIL-3 classical diagnostic procedures for the diagnosis of invasive fungal diseases in patients with leukaemia. Bone Marrow Transplant 2012; 47: 1030-1045.
34. Arendrup M, Jensen IP, Justesen T. Diagnosing bacteremia at a Danish hospital using one early large blood volume for culture. Scand J Infect Dis 1996; 28: 609-614.
35. Arendrup MC, Sulim S, Holm A et al. Diagnostic issues, clinical characteristics, and outcomes for patients with fungemia. J Clin Microbiol 2011; 49: 3300-3308.
36. Ericson EL, Klingspor L, Ullberg M, Ozenci V. Clinical comparison of the Bactec Mycosis IC/F, BacT/Alert FA, and BacT/Alert FN blood culture vials for the detection of candidemia. Diagn Microbiol Infect Dis 2012; 73: 153-156.
37. Horvath LL, George BJ, Murray CK, Harrison LS, Hospenthal DR. Direct comparison of the BACTEC 9240 and BacT/ALERT 3D automated blood culture systems for candida growth detection. J Clin Microbiol 2004; 42: 115-118.
38. Cateau E, Cognee AS, Tran TC et al. Impact of yeast-bacteria coinfection on the detection of Candida sp. in an automated blood culture system. Diagn Microbiol Infect Dis 2012; 72: 328-331.
39. Fonseca A, Fell JW, Boekhout T. Cryptococcus Vuillemin (1901). In: Kurtzman CP, Fell JW, Boekhout T, eds. The yeasts, a taxonomic study, 5th edn. Amsterdam: Elsevier, 2011; 1616-1737.
40. Dromer F, Lortholary O. Cryptococcosis. In: Magill A, Ryan E, Solomon T, Hill D, eds. Hunter's tropical medicine and emerging infectious disease, 9th edn. Amsterdam: Elsevier, 2012; 1214.
41. Perfect JR, Dismukes WE, Dromer F et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010; 50: 291-322.
42. Singh N, Dromer F, Perfect JR, Lortholary O. Cryptococcosis in solid organ transplant recipients: current state of the science. Clin Infect Dis 2008; 47: 1321-1327.
43. Jarvis JN, Dromer F, Harrison TS, Lortholary O. Managing cryptococcosis in the immunocompromised host. Curr Opin Infect Dis 2008; 21: 596-603.
44. Khawcharoenporn T, Apisarnthanarak A, Mundy LM. Non-neoformans cryptococcal infections: a systematic review. Infection 2007; 35: 51-58.
45. McCurdy LH, Morrow JD. Infections due to non-neoformans cryptococcal species. Compr Ther 2003; 29: 95-101.
46. Pan W, Liao W, Hagen F et al. Meningitis caused by Filobasidium uniguttulatum: case report and overview of the literature. Mycoses 2012; 55: 105-109.
47. Tintelnot K, Losert H. Isolation of Cryptococcus adeliensis from clinical samples and the environment in Germany. J Clin Microbiol 2005; 43: 1007.
48. Rimek D, Haase G, Luck A, Casper J, Podbielski A. First report of a case of meningitis caused by Cryptococcus adeliensis in a patient with acute myeloid leukemia. J Clin Microbiol 2004; 42: 481-483.
49. Bernal-Martinez L, Gomez-Lopez A, Castelli MV et al. Susceptibility profile of clinical isolates of non-Cryptococcus neoformans/non-Cryptococcus gattii Cryptococcus species and literature review. Med Mycol 2010; 48: 90-96.
50. Burnik C, Altintas ND, Ozkaya G et al. Acute respiratory distress syndrome due to Cryptococcus albidus pneumonia: case report and review of the literature. Med Mycol 2007; 45: 469-473.
51. Okoli I, Oyeka CA, Kwon-Chung KJ et al. Cryptotrichosporon anacardii gen. nov., sp. nov., a new trichosporonoid capsulate basidiomycetous yeast from Nigeria that is able to form melanin on niger seed agar. FEMS Yeast Res 2007; 7: 339-350.
52. Petter R, Kang B, Boekhout T, Davis B, Kwon-Chung K. A survey of heterobasidiomycetous yeasts for the presence of the genes homologous to virulence factors of Filobasidiella neoformans, CNLAC1 and CAP59. Microbiology 2001; 147: 2029-2036.
53. Bovers M, Diaz MR, Hagen F et al. Identification of genotypically diverse Cryptococcus neoformans and Cryptococcus gattii isolates by Luminex xMAP technology. J Clin Microbiol 2007; 45: 1874-1883.
54. Firacative C, Trilles L, Meyer W. MALDI-TOF MS enables the rapid identification of the major molecular types within the Cryptococcus neoformans/C. gattii species complex. PLoS ONE 2012; 7: e37566.
55. McTaggart LR, Lei E, Richardson SE, Hoang L, Fothergill A, Zhang SX. Rapid identification of Cryptococcus neoformans and Cryptococcus gattii by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol 2011; 49: 3050-3053.
56. Posteraro B, Vella A, Cogliati M et al. Matrix-assisted laser desorption ionization-time of flight mass spectrometry-based method for discrimination between molecular types of Cryptococcus neoformans and Cryptococcus gattii. J Clin Microbiol 2012; 50: 2472-2476.
57. Fekkar A, Brun S, D'Ussel M et al. Serum cross-reactivity with Aspergillus Galactomannan and Cryptococcal antigen during fatal disseminated Trichosporon dermatis infection. Clin Infect Dis 2009; 49: 1457-1458.
58. Lyman CA, Devi SJ, Nathanson J, Frasch CE, Pizzo PA, Walsh TJ. Detection and quantitation of the glucuronoxylomannan-like polysaccharide antigen from clinical and nonclinical isolates of Trichosporon beigelii and implications for pathogenicity. J Clin Microbiol 1995; 33: 126-130.
59. Yeo SF, Wong B. Current status of nonculture methods for diagnosis of invasive fungal infections. Clin Microbiol Rev 2002; 15: 465-484.
60. Westerink MA, Amsterdam D, Petell RJ, Stram MN, Apicella MA. Septicemia due to DF-2. Cause of a false-positive cryptococcal latex agglutination result. Am J Med 1987; 83: 155-158.
61. Chanock SJ, Toltzis P, Wilson C. Cross-reactivity between Stomatococcus mucilaginosus and latex agglutination for cryptococcal antigen. Lancet 1993; 342: 1119-1120.
62. Blevins LB, Fenn J, Segal H, Newcomb-Gayman P, Carroll KC. False-positive cryptococcal antigen latex agglutination caused by disinfectants and soaps. J Clin Microbiol 1995; 33: 1674-1675.
63. Odabasi Z, Paetznick VL, Rodriguez JR, Chen E, McGinnis MR, Ostrosky-Zeichner L. Differences in β-glucan levels in culture supernatants of a variety of fungi. Med Mycol 2006; 44: 267-272.
64. Ostrosky-Zeichner L, Alexander BD, Kett DH et al. Multicenter clinical evaluation of the (1→3) β-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41: 654-659.
65. Dalle F, Charles PE, Blanc K et al. Cryptococcus neoformans galactoxylomannan contains an epitope(s) that is cross-reactive with Aspergillus galactomannan. J Clin Microbiol 2005; 43: 2929-2931.
66. McMullan BJ, Halliday C, Sorrell TC et al. Clinical utility of the cryptococcal antigen lateral flow assay in a diagnostic mycology laboratory. PLoS ONE 2012; 7: e49541.
67. Hansen J, Slechta ES, Gates-Hollingsworth MA et al. Large scale evaluation of the Immuno-Mycologics Inc. (IMMY) lateral flow and enzyme-linked immunoassays for the detection of cryptococcal antigen in serum and cerebrospinal fluid. Clin Vaccine Immunol 2013; 20: 52-55.
68. Jarvis JN, Percival A, Bauman S et al. Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clin Infect Dis 2011; 53: 1019-1023.
69. Serena C, Pastor FJ, Ortoneda M, Capilla J, Nolard N, Guarro J. In vitro antifungal susceptibilities of uncommon basidiomycetous yeasts. Antimicrob Agents Chemother 2004; 48: 2724-2726.
70. Quindos G, Ruesga MT, Martin-Mazuelos E et al. In-vitro activity of 5-fluorocytosine against 1, 021 Spanish clinical isolates of Candida and other medically important yeasts. Rev Iberoam Micol 2004; 21: 63-69.
71. Shimokawa O, Niimi M, Kikuchi K, Saito M, Kajiwara H, Yoshida S. Relationship between MIC and minimum sterol 14α-demethylation-inhibitory concentration as a factor in evaluating activities of azoles against various fungal species. J Clin Microbiol 2005; 43: 5547-5549.
72. Pedroso RS, Ferreira JC, Candido RC. In vitro susceptibility to antifungal agents of environmental Cryptococcus spp. isolated in the city of Ribeirao Preto, Sao Paulo, Brazil. Mem Inst Oswaldo Cruz 2006; 101: 239-243.
73. Kordossis T, Avlami A, Velegraki A et al. First report of Cryptococcus laurentii meningitis and a fatal case of Cryptococcus albidus cryptococcaemia in AIDS patients. Med Mycol 1998; 36: 335-339.
74. Garcia-Martos P, Noval JF, Garcia-Tapia A, Marin P, Puerto JL, Sepulveda A. Susceptibility to antifungal agents of Cryptococcus species of clinical interest. Med Clin (Barc) 2002; 119: 211-213.
75. Kassamali H, Anaissie E, Ro J et al. Disseminated Geotrichum candidum infection. J Clin Microbiol 1987; 25: 1782-1783.
76. Anaissie E, Bodey GP, Kantarjian H et al. New spectrum of fungal infections in patients with cancer. Rev Infect Dis 1989; 11: 369-378.
77. Henrich TJ, Marty FM, Milner DA Jr, Thorner AR. Disseminated Geotrichum candidum infection in a patient with relapsed acute myelogenous leukemia following allogeneic stem cell transplantation and review of the literature. Transpl Infect Dis 2009; 11: 458-462.
78. Sfakianakis A, Krasagakis K, Stefanidou M et al. Invasive cutaneous infection with Geotrichum candidum - sequential treatment with amphotericin B and voriconazole. Med Mycol 2007; 45: 81-84.
79. Andre N, Coze C, Gentet JC, Perez R, Bernard JL. Geotrichum candidum septicemia in a child with hepatoblastoma. Pediatr Infect Dis J 2004; 23: 86.
80. Ng KP, Soo-Hoo TS, Koh MT, Kwan PW. Disseminated Geotrichum infection. Med J Malaysia 1994; 49: 424-426.
81. Wildfeuer A, Seidl HP, Paule I, Haberreiter A. In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin. Mycoses 1998; 41: 309-319.
82. Cordoba S, Vivot W, Bosco-Borgeat ME et al. Species distribution and susceptibility profile of yeasts isolated from blood cultures: results of a multicenter active laboratory-based surveillance study in Argentina. Rev Argent Microbiol 2011; 43: 176-185.
83. Taj-Aldeen SJ, Doiphode SH, Han XY. Kodamaea (Pichia) ohmeri fungaemia in a premature neonate. J Med Microbiol 2006; 55: 237-239.
84. Chakrabarti A, Rudramurthy SM, Kale P et al. Kodamaea ohmeri fungemia is not an uncommon entity in india: need for a systematic study. IDSA annual meeting 2010; M-652.
85. De Barros JD, Do Nascimento SM, De Araujo FJ et al. Kodamaea (Pichia) ohmeri fungemia in a pediatric patient admitted in a public hospital. Med Mycol 2009; 47: 775-779.
86. Al-Sweih N, Khan ZU, Ahmad S et al. Kodamaea ohmeri as an emerging pathogen: a case report and review of the literature. Med Mycol 2011; 49: 766-770.
87. Sundaram PS, Bijulal S, Tharakan JA, Antony M. Kodamaea ohmeri tricuspid valve endocarditis with right ventricular inflow obstruction in a neonate with structurally normal heart. Ann Pediatr Cardiol 2011; 4: 77-80.
88. Santino I, Bono S, Borruso L et al. Kodamaea ohmeri isolate from two immunocompromised patients: first report in Italy. Mycoses 2013; 56: 179-181.
89. Menon T, Herrera M, Periasamy S, Palanivelu V, Sikhamani R, Wickes B. Oral candidiasis caused by Kodamaea ohmeri in a HIV patient in Chennai, India. Mycoses 2010; 53: 458-459.
90. Mahfouz RA, Otrock ZK, Mehawej H, Farhat F. Kodamaea (Pichia) ohmeri fungaemia complicating acute myeloid leukaemia in a patient with haemochromatosis. Pathology 2008; 40: 99-101.
91. Chiu CH, Wang YC, Shang ST, Chang FY. Kodamaea ohmeri fungaemia successfully treated with caspofungin. Int J Antimicrob Agents 2010; 35: 98-99.
92. Yang BH, Peng MY, Hou SJ, Sun JR, Lee SY, Lu JJ. Fluconazole-resistant Kodamaea ohmeri fungemia associated with cellulitis: case report and review of the literature. Int J Infect Dis 2009; 13: e493-e497.
93. Shaaban H, Choo HF, Boghossian J, Perez G. Kodamaea ohmeri fungemia in an immunocompetent patient treated with micafungin: case report and review of the literature. Mycopathologia 2010; 170: 223-228.
94. Lee JS, Shin JH, Kim MN et al. Kodamaea ohmeri isolates from patients in a university hospital: identification, antifungal susceptibility, and pulsed-field gel electrophoresis analysis. J Clin Microbiol 2007; 45: 1005-1010.
95. Otag F, Kuyucu N, Erturan Z, Sen S, Emekdas G, Sugita T. An outbreak of Pichia ohmeri infection in the paediatric intensive care unit: case reports and review of the literature. Mycoses 2005; 48: 265-269.
96. Reina JP, Larone DH, Sabetta JR, Krieger KK, Hartman BJ. Pichia ohmeri prosthetic valve endocarditis and review of the literature. Scand J Infect Dis 2002; 34: 140-141.
97. Gaitanis G, Magiatis P, Hantschke M, Bassukas ID, Velegraki A. The Malassezia genus in skin and systemic diseases. Clin Microbiol Rev 2012; 25: 106-141.
98. Chang HJ, Miller HL, Watkins N et al. An epidemic of Malassezia pachydermatis in an intensive care nursery associated with colonization of health care workers' pet dogs. N Engl J Med 1998; 338: 706-711.
99. Gueho E, Simmons RB, Pruitt WR, Meyer SA, Ahearn DG. Association of Malassezia pachydermatis with systemic infections of humans. J Clin Microbiol 1987; 25: 1789-1790.
100. Morris DO. Malassezia pachydermatis carriage in dog owners. Emerg Infect Dis 2005; 11: 83-88.
101. Chryssanthou E, Broberger U, Petrini B. Malassezia pachydermatis fungaemia in a neonatal intensive care unit. Acta Paediatr 2001; 90: 323-327.
102. Mickelsen PA, Viano-Paulson MC, Stevens DA, Diaz PS. Clinical and microbiological features of infection with Malassezia pachydermatis in high-risk infants. J Infect Dis 1988; 157: 1163-1168.
103. van Belkum A, Boekhout T, Bosboom R. Monitoring spread of Malassezia infections in a neonatal intensive care unit by PCR-mediated genetic typing. J Clin Microbiol 1994; 32: 2528-2532.
104. Redline RW, Redline SS, Boxerbaum B, Dahms BB. Systemic Malassezia furfur infections in patients receiving intralipid therapy. Hum Pathol 1985; 16: 815-822.
105. Morrison VA, Weisdorf DJ. The spectrum of Malassezia infections in the bone marrow transplant population. Bone Marrow Transplant 2000; 26: 645-648.
106. Tragiannidis A, Bisping G, Koehler G, Groll AH. Minireview: Malassezia infections in immunocompromised patients. Mycoses 2010; 53: 187-195.
107. Marcon MJ, Powell DA, Durrell DE. Methods for optimal recovery of Malassezia furfur from blood culture. J Clin Microbiol 1986; 24: 696-700.
108. Nelson SC, Yau YC, Richardson SE, Matlow AG. Improved detection of Malassezia species in lipid-supplemented Peds Plus blood culture bottles. J Clin Microbiol 1995; 33: 1005-1007.
109. Guillot J, Gueho E. The diversity of Malassezia yeasts confirmed by rRNA sequence and nuclear DNA comparisons. Antonie Van Leeuwenhoek 1995; 67: 297-314.
110. Sugita T, Suzuki M, Goto S et al. Quantitative analysis of the cutaneous Malassezia microbiota in 770 healthy Japanese by age and gender using a real-time PCR assay. Med Mycol 2010; 48: 229-233.
111. Gupta AK, Boekhout T, Theelen B, Summerbell R, Batra R. Identification and typing of Malassezia species by amplified fragment length polymorphism and sequence analyses of the internal transcribed spacer and large-subunit regions of ribosomal DNA. J Clin Microbiol 2004; 42: 4253-4260.
112. Guého-Kellermann E, Boekhout T, Begerow D. Biodiversity, phylogeny and ultrastructure. In: Boekhout T, Gueho E, Mayser P, Velegraki A, eds. Malassezia and the skin. Science and clinical practice. Heidelberg: Springer, 2010; 17-63.
113. Cafarchia C, Figueredo LA, Favuzzi V et al. Assessment of the antifungal susceptibility of Malassezia pachydermatis in various media using a CLSI protocol. Vet Microbiol 2012; 159: 536-540.
114. Jesus FPK, Lautert C, Zanette RA et al. In vitro susceptibility of fluconazole-susceptible and -resistant isolates of Malassezia pachydermatis against azoles. Vet Microbiol 2011; 152: 161-164.
115. Cafarchia C, Figueredo LA, Iatta R, Colao V, Montagna MT, Otranto D. In vitro evaluation of Malassezia pachydermatis susceptibility to azole compounds using E-test and CLSI microdilution methods. Med Mycol 2012; 50: 795-801.
116. Ashbee HR. Update on the genus Malassezia. Med Mycol 2007; 45: 287-303.
117. Devlin RK. Invasive fungal infections caused by Candida and Malassezia species in the neonatal intensive care unit. Adv Neonatal Care 2006; 6: 68-77.
118. Gerin M, Mahlaoui N, Elie C et al. Therapeutic drug monitoring of voriconazole after intravenous administration in infants and children with primary immunodeficiency. Ther Drug Monit 2011; 33: 464-466.
119. Pieper S, Kolve H, Gumbinger HG, Goletz G, Würthwein G, Groll AH. Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients. J Antimicrob Chemother 2012; 67: 2717-2724.
120. Bartelink IH, Wolfs T, Jonker M et al. Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients. Antimicrob Agents Chemother 2013; 57: 235-240.
121. Sugita T, Takashima M, Poonwan N et al. The first isolation of ustilaginomycetous anamorphic yeasts, Pseudozyma species, from patients' blood and a description of two new species: P. parantarctica and P. thailandica. Microbiol Immunol 2003; 47: 183-190.
122. Lin SS, Pranikoff T, Smith SF et al. Central venous catheter infection associated with Pseudozyma aphidis in a child with short gut syndrome. J Med Microbiol 2008; 57: 516-518.
123. Prakash A, Wankhede S, Singh PK et al. First neonatal case of fungemia due to Pseudozyma aphidis and a global literature review. Mycoses 2013. doi: 10.1111/myc.12098. [Epub ahead of print].
124. de Carvalho Parahym AMR, da Silva CM, Domingos IDF et al. Pulmonary infection due to Pseudozyma aphidis in a patient with Burkitt lymphoma: first case report. Diagn Microbiol Infect Dis 2013; 75: 104-106.
125. Hwang S, Kim J, Yoon S et al. First report of brain abscess associated with Pseudozyma species in a patient with astrocytoma. Korean J Lab Med 2013; 30: 284-288.
126. Chen B, Zhu LY, Xuan X et al. Isolation of both Pseudozyma aphidis and Nocardia otitidiscaviarum from a mycetoma on the leg. Int J Dermatol 2011; 50: 714-719.
127. Wirth F, Goldani LZ. Epidemiology of Rhodotorula: an emerging pathogen. Interdiscip Perspect Infect Dis 2012; 2012: 465717.
128. Sampaio JP. Rhodotorula Harrison (1928). In: Kurtzman CP, Fell JW, Boekhout T, eds. The yeasts, a taxonomic study, 5th edn. Amsterdam: Elsevier, 2011; 1873-1927.
129. Biswas SK, Yokoyama K, Nishimura K, Miyaji M. Molecular phylogenetics of the genus Rhodotorula and related basidiomycetous yeasts inferred from the mitochondrial cytochrome b gene. Int J Syst Evol Microbiol 2001; 51: 1191-1199.
130. Tuon FF, Costa SF. Rhodotorula infection. A systematic review of 128 cases from literature. Rev Iberoam Micol 2008; 25: 135-140.
131. Garcia-Suarez J, Gomez-Herruz P, Cuadros JA, Burgaleta C. Epidemiology and outcome of Rhodotorula infection in haematological patients. Mycoses 2011; 54: 318-324.
132. Tuon FF, de Almeida GM, Costa SF. Central venous catheter-associated fungemia due to Rhodotorula spp. - a systematic review. Med Mycol 2007; 45: 441-447.
133. Miceli MH, Diaz JA, Lee SA. Emerging opportunistic yeast infections. Lancet Infect Dis 2011; 11: 142-151.
134. Lunardi LW, Aquino VR, Zimerman RA, Goldani LZ. Epidemiology and outcome of Rhodotorula fungemia in a tertiary care hospital. Clin Infect Dis 2006; 43: e60-e63.
135. Fores R, Ramos A, Orden B et al. Rhodotorula species fungaemia causes low mortality in haematopoietic stem-cell transplantation. A case report and review. Mycoses 2012; 55: e158-e162.
136. Perniola R, Faneschi ML, Manso E et al. Rhodotorula mucilaginosa outbreak in neonatal intensive care unit: microbiological features, clinical presentation, and analysis of related variables. Eur J Clin Microbiol Infect Dis 2006; 25: 193-196.
137. Gyaurgieva OH, Bogomolova TS, Gorshkova GI. Meningitis caused by Rhodotorula rubra in an HIV-infected patient. J Med Vet Mycol 1996; 34: 357-359.
138. Unal A, Koc AN, Sipahioglu MH et al. CAPD-related peritonitis caused by Rhodotorula mucilaginosa. Perit Dial Int 2009; 29: 581-582.
139. Maeder M, Vogt PR, Schaer G, von Graevenitz A, Gunthard HF. Aortic homograft endocarditis caused by Rhodotorula mucilaginosa. Infection 2003; 31: 181-183.
140. Baradkar VP, Kumar S. Meningitis caused by Rhodotorula mucilaginosa in human immunodeficiency virus seropositive patient. Ann Indian Acad Neurol 2008; 11: 245-247.
141. Elias ML, Soliman AK, Mahoney FJ et al. Isolation of Cryptococcus, Candida, Aspergillus, Rhodotorula and Nocardia from meningitis patients in Egypt. J Egypt Public Health Assoc 2009; 84: 169-181.
142. Savini V, Sozio F, Catavitello C et al. Femoral prosthesis infection by Rhodotorula mucilaginosa. J Clin Microbiol 2008; 46: 3544-3545.
143. Shinde RS, Mantur BG, Patil G, Parande MV, Parande AM. Meningitis due to Rhodotorula glutinis in an HIV infected patient. Indian J Med Microbiol 2008; 26: 375-377.
144. Villar JM, Velasco CG, Delgado JD. Fungemia due to Rhodotorula mucilaginosa in an immunocompetent, critically ill patient. J Infect Chemother 2012; 18: 581-583.
145. Pinna A, Carta F, Zanetti S, Sanna S, Sechi LA. Endogenous Rhodotorula minuta and Candida albicans endophthalmitis in an injecting drug user. Br J Ophthalmol 2001; 85: 754.
146. Spiliopoulou A, Anastassiou ED, Christofidou M. Rhodotorula fungemia of an intensive care unit patient and review of published cases. Mycopathologia 2012; 174: 301-309.
147. Mori T, Nakamura Y, Kato J et al. Fungemia due to Rhodotorula mucilaginosa after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2012; 14: 91-94.
148. Garcia-Suarez J, Gomez-Herruz P, Cuadros JA, Guillen H, Burgaleta C. Rhodotorula mucilaginosa catheter-related fungaemia in a patient with multiple myeloma. Mycoses 2011; 54: e214-e216.
149. Poikonen E, Lyytikainen O, Anttila VJ et al. Secular trend in candidemia and the use of fluconazole in Finland, 2004-2007. BMC Infect Dis 2010; 10: 312.
150. Khodavaisy S, Nabili M, Davari B, Vahedi M. Evaluation of bacterial and fungal contamination in the health care workers' hands and rings in the intensive care unit. J Prev Med Hyg 2011; 52: 215-218.
151. Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 2004; 42: 4419-4431.
152. Hall L, Le Febre KM, Deml SM, Wohlfiel SL, Wengenack NL. Evaluation of the yeast traffic light PNA FISH probes for identification of Candida species from positive blood cultures. J Clin Microbiol 2012; 50: 1446-1448.
153. Diekema DJ, Petroelje B, Messer SA, Hollis RJ, Pfaller MA. Activities of available and investigational antifungal agents against Rhodotorula species. J Clin Microbiol 2005; 43: 476-478.
154. Nunes JM, Bizerra FC, Ferreira RC, Colombo AL. Molecular identification, antifungal susceptibility profile and biofilm formation of clinical and environmental Rhodotorula spp. isolates. Antimicrob Agents Chemother 2013; 57: 382-389.
155. Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope WW; The European Committee on Antimicrobial Susceptibility Testing Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST). EUCAST technical note on Aspergillus and amphotericin-B, itraconazole, and posaconazole. Clin Microbiol Infect 2012; 17: E248-E250.
156. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). EUCAST technical note on voriconazole. Clin Microbiol Infect 2008; 14: 985-987.
157. Hope WW, Cuenca-Estrella M, Lass-Florl C, Arendrup MC. EUCAST technical note on voriconazole and Aspergillus spp. Clin Microbiol Infect 2013; 19: E278-E280.
158. Preney L, Theraud M, Guiguen C, Gangneux JP. Experimental evaluation of antifungal and antiseptic agents against Rhodotorula spp. Mycoses 2003; 46: 492-495.
159. Gomez-Lopez A, Mellado E, Rodriguez-Tudela JL, Cuenca-Estrella M. Susceptibility profile of 29 clinical isolates of Rhodotorula spp. and literature review. J Antimicrob Chemother 2005; 55: 312-316.
160. Caira M, Trecarichi EM, Tumbarello M, Leone G, Pagano L. Uncommon yeast infections in hematological patients: from diagnosis to treatment. Expert Rev Anti Infect Ther 2011; 9: 1067-1075.
161. Anatoliotaki M, Mantadakis E, Galanakis E, Samonis G. Rhodotorula species fungemia: a threat to the immunocompromised host. Clin Lab 2003; 49: 49-55.
162. de Zoysa JR, Searle M, Lynn KL, Robson RA. Successful treatment of CAPD peritonitis caused by Rhodotorula mucilaginosa. Perit Dial Int 2001; 21: 627-628.
163. Asim M, Meigh JA, Farr MJ. Fungal peritonitis caused by Candida parapsilosis and subsequently Rhodotorula glutinis in a CAPD patient. Perit Dial Int 1999; 19: 183.
164. Samonis G, Anatoliotaki M, Apostolakou H, Maraki S, Mavroudis D, Georgoulias V. Transient fungemia due to Rhodotorula rubra in a cancer patient: case report and review of the literature. Infection 2001; 29: 173-176.
165. Edwards-Ingram LC, Gent ME, Hoyle DC, Hayes A, Stateva LI, Oliver SG. Comparative genomic hybridization provides new insights into the molecular taxonomy of the Saccharomyces sensu stricto complex. Genome Res 2004; 14: 1043-1051.
166. Edwards-Ingram L, Gitsham P, Burton N et al. Genotypic and physiological characterization of Saccharomyces boulardii, the probiotic strain of Saccharomyces cerevisiae. Appl Environ Microbiol 2007; 73: 2458-2467.
167. Riaz M, Alam S, Malik A, Ali SM. Efficacy and safety of Saccharomyces boulardii in acute childhood diarrhea: a double blind randomised controlled trial. Indian J Pediatr 2012; 79: 478-482.
168. de Llanos R, Llopis S, Molero G, Querol A, Gil C, Fernandez-Espinar MT. In vivo virulence of commercial Saccharomyces cerevisiae strains with pathogenicity-associated phenotypical traits. Int J Food Microbiol 2011; 144: 393-399.
169. Czeruckat D, Piche P, Rampal P. Review article: yeast as probiotics - Saccharomyces boulardii. Aliment Pharmacol Ther 2007; 26: 767-778.
170. Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol 2005; 43: 2155-2162.
171. Thygesen JB, Glerup H, Tarp B. Saccharomyces boulardii fungemia caused by treatment with a probioticum. BMJ Case Rep 2012. doi: 10.1136/bcr.06.2011.4412
172. Stefanatou E, Kompoti M, Paridou A et al. Probiotic sepsis due to Saccharomyces fungaemia in a critically ill burn patient. Mycoses 2011; 54: e643-e646.
173. Basseti S, Frei R, Zimmerli W. Fungemia with Saccharomyces cerevisiae after treatment with Saccharomyces boulardii. Am J Med 1998; 105: 71-72.
174. de Llanos R, Querol A, Pemán J, Gobernado M, Fernandez-Espinar MT. Food and probiotic strains from the Saccharomyces cerevisiae species as a possible origin of human systemic infections. Int J Food Microbiol 2006; 110: 286-290.
175. Herbrecht R, Nivoix Y. Saccharomyces cerevisiae fungemia: an adverse effect of Saccharomyces boulardii probiotic administration. Clin Infect Dis 2005; 40: 1635-1637.
176. Munoz P, Bouza E, Cuenca-Estrella M et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 2005; 40: 1625-1634.
177. Graf C, Gavazzi G. Saccharomyces cerevisiae fungemia in an immunocompromised patient not treated with Saccharomyces boulardii preparation. J Infect 2007; 54: 310-311.
178. Enache-Angoulvant A, Hennequin C. Invasive Saccharomyces infection: a comprehensive review. Clin Infect Dis 2005; 41: 1559-1568.
179. Rimek D, Redetzke K, Singh J, Heinrich K, Kappe R. Performance des Candida-Mannan-Antigennachweises bei Patienten mit Fungämien. Mycoses 2004; 47: 23-26.
180. Yoshida M, Obayashi T, Iwama A et al. Detection of plasma (1→3)-β-D-glucan in patients with Fusarium, Trichosporon, Saccharomyces and Acremonium fungaemias. J Med Vet Mycol 1997; 35: 371-374.
181. Thompson GR III, Wiederhold NP, Sutton DA, Fothergill A, Patterson TF. In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species. J Antimicrob Chemother 2009; 64: 79-83.
182. Lolis N, Veldekis D, Moraitou H et al. Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin. Crit Care 2008; 12: 414.
183. Choi G, Meijer SL, Hazenberg MD. Disseminated bread yeast fungaemia in a baker's wife with acute myeloid leukaemia. Br J Haematol 2012; 158: 298.
184. Tiballi RN, Spiegel JE, Zarins LT, Kauffman CA. Saccharomyces cerevisiae infections and antifungal susceptibility studies by colorimetric and broth macrodilution methods. Diagn Microbiol Infect Dis 1995; 23: 135-140.
185. Hamoud S, Keidar Z, Hayek T. Recurrent Saccharomyces cerevisiae fungemia in an otherwise healthy patient. Isr Med Assoc J 2011; 13: 575-576.
186. Gadea I, Cuenca-Estrella M, Prieto E et al. Genotyping and antifungal susceptibility profile of Dipodascus capitatus isolates causing disseminated infection in seven hematological patients of a tertiary hospital. J Clin Microbiol 2004; 42: 1832-1836.
187. Aalbaek B, Stenderup J, Jensen HE, Valbak J, Nylin B, Huda A. Mycotic and algal bovine mastitis in Denmark. APMIS 1994; 102: 451-456.
188. Döǧen A, Kaplan E, Öksüz Z, Serin MS, Lkit M, de Hoog GS. Dishwashers are a major source of human opportunistic yeast-like fungi in indoor environments in Mersin, Turkey. Med Mycol 2013; 51: 493-498.
189. Martino P, Girmenia C, Venditti M et al. Spontaneous pneumothorax complicating pulmonary mycetoma in patients with acute leukemia. Rev Infect Dis 1990; 12: 611-617.
190. Birrenbach T, Bertschy S, Aebersold F et al. Emergence of Blastoschizomyces capitatus yeast infections, Central Europe. Emerg Infect Dis 2012; 18: 98-101.
191. Christakis G, Perlorentzou S, Aslanidou M, Megalakaki A, Velegraki A. Fatal Blastoschizomyces capitatus sepsis in a neutropenic patient with acute myeloid leukemia: first documented case from Greece. Mycoses 2005; 48: 216-220.
192. Girmenia C, Pagano L, Martino B et al. Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature. J Clin Microbiol 2005; 43: 1818-1828.
193. Martino R, Salavert M, Parody R et al. Blastoschizomyces capitatus infection in patients with leukemia: report of 26 cases. Clin Infect Dis 2004; 38: 335-341.
194. DeMaio J, Colman L. The use of adjuvant interferon-γ therapy for hepatosplenic Blastoschizomyces capitatus infection in a patient with leukemia. Clin Infect Dis 2000; 31: 822-824.
195. Pagano L, Morace G, Ortu-La BE, Sanguinetti M, Leone G. Adjuvant therapy with rhGM-CSF for the treatment of Blastoschizomyces capitatus systemic infection in a patient with acute myeloid leukemia. Ann Hematol 1996; 73: 33-34.
196. Cofrancesco E, Viviani MA, Boschetti C, Tortorano AM, Balzani A, Castagnone D. Treatment of chronic disseminated Geotrichum capitatum infection with high cumulative dose of colloidal amphotericin B and itraconazole in a leukaemia patient. Mycoses 1995; 38: 377-384.
197. Oravcova E, Lacka J, Drgona L et al. Funguria in cancer patients: analysis of risk factors, clinical presentation and outcome in 50 patients. Infection 1996; 24: 319-323.
198. Schiemann R, Glasmacher A, Bailly E et al. Geotrichum capitatum septicaemia in neutropenic patients: case report and review of the literature. Mycoses 1998; 41: 113-116.
199. Cheung MY, Chiu NC, Chen SH, Liu HC, Ou CT, Liang DC. Mandibular osteomyelitis caused by Blastoschizomyces capitatus in a child with acute myelogenous leukemia. J Formos Med Assoc 1999; 98: 787-789.
200. Celik A, Ozaras R, Kantarcioglu S, Mert A, Tabak F, Ozturk R. Spondylodiscitis due to an emergent fungal pathogen: Blastoschizomyces capitatus, a case report and review of the literature. Rheumatol Int 2009; 29: 1237-1241.
201. Lapusan S, Dimicoli S, Marjanovic Z et al. Immune reconstitution inflammatory syndrome following allo-SCT in a patient with Dipodascus capitatus spondylodiscitis. Bone Marrow Transplant 2011; 46: 1265-1267.
202. D'Antonio D, Mazzoni A, Iacone A et al. Emergence of fluconazole-resistant strains of Blastoschizomyces capitatus causing nosocomial infections in cancer patients. J Clin Microbiol 1996; 34: 753-755.
203. Gurgui M, Sanchez F, March F et al. Nosocomial outbreak of Blastoschizomyces capitatus associated with contaminated milk in a haematological unit. J Hosp Infect 2011; 78: 274-278.
204. Polacheck I, Salkin IF, Kitzes-Cohen R, Raz R. Endocarditis caused by Blastoschizomyces capitatus and taxonomic review of the genus. J Clin Microbiol 1992; 30: 2318-2322.
205. Wills TS, Degryse A, Lavina J, Sinnott JT. Blastoschizomyces capitatus pneumonia in an immunocompetent male. South Med J 2004; 97: 702-704.
206. Mathews MS, Sen S. Blastoschizomyces capitatus infection after contamination of fluids for intravenous application. Mycoses 1998; 41: 427-428.
207. Naficy AB, Murray HW. Isolated meningitis caused by Blastoschizomyces capitatus. J Infect Dis 1990; 161: 1041-1042.
208. Giacchino M, Chiapello N, Bezzio S et al. Aspergillus galactomannan enzyme-linked immunosorbent assay cross-reactivity caused by invasive Geotrichum capitatum. J Clin Microbiol 2006; 44: 3432-3434.
209. Bonini A, Capatti C, Parmeggiani M et al. Galactomannan detection in Geotrichum capitatum invasive infections: report of 2 new cases and review of diagnostic options. Diagn Microbiol Infect Dis 2008; 62: 450-452.
210. Girmenia C, Pizzarelli G, D'Antonio D, Cristini F, Martino P. In vitro susceptibility testing of Geotrichum capitatum: comparison of the E-test, disk diffusion, and Sensititre colorimetric methods with the NCCLS M27-A2 broth microdilution reference method. Antimicrob Agents Chemother 2003; 47: 3985-3988.
211. Chittick P, Palavecino EL, Delashmitt B, Evans J, Peacock JE. Case of fatal Blastoschizomyces capitatus infection occurring in a patient receiving empiric micafungin therapy. Antimicrob Agents Chemother 2009; 53: 5306-5307.
212. Schuermans C, van Bergen M, Coorevits L et al. Breakthrough Saprochaete capitata infections in patients receiving echinocandins: case report and review of the literature. Med Mycol 2011; 49: 414-418.
213. Serena C, Marine M, Marimon R, Pastor FJ, Guarro J. Effect of antifungal treatment in a murine model of blastoschizomycosis. Int J Antimicrob Agents 2007; 29: 79-83.
214. Ikuta K, Torimoto Y, Yamamoto M et al. Successful treatment of systemic Geotrichum capitatum infection by liposomal amphotericin-B, itraconazole, and voriconazole in a Japanese man. Intern Med 2010; 49: 2499-2503.
215. Etienne A, Datry A, Gaspar N, Morel V, Delabesse E, Lmimouni B, et al. Successful treatment of disseminated Geotrichum capitatum infection with a combination of caspofungin and voriconazole in an immunocompromised patient. Mycoses 2008; 51: 270-272.
216. Fianchi L, Montini L, Caira M et al. Combined voriconazole plus caspofungin therapy for the treatment of probable Geotrichum pneumonia in a leukemia patient. Infection 2008; 36: 65-67.
217. Perez-Sanchez I, Anguita J, Rabadan PM et al. Blastoschizomyces capitatus infection in acute leukemia patients. Leuk Lymphoma 2000; 39: 209-212.
218. Hamamoto M, Boekhout T, Nakase T. Sporobolomyces Klyver & van Niel (1914). In: Kurtzman CP, Fell JW, Boekhout T, eds. The yeasts, a taxonomic study, 5th edn. Amsterdam: Elsevier, 2011; 1929-1990.
219. Fairs A, Wardlaw AJ, Thompson J, Pashley CH. Guidelines on ambient intramural airborne fungal spores. J Investig Allergol Clin Immunol 2010; 20: 490-498.
220. Moore JE, Xu J, Millar BC, Elshibly S. Edible dates (Phoenix dactylifera), a potential source of Cladosporium cladosporioides and Sporobolomyces roseus: implications for public health. Mycopathologia 2002; 154: 25-28.
221. Watanabe M, Tsutsumi F, Konuma R et al. Quantitative analysis of mycoflora on commercial domestic fruits in Japan. J Food Prot 2011; 74: 1488-1499.
222. Morris JT, Beckius M, McAllister CK. Sporobolomyces infection in an AIDS patient. J Infect Dis 1991; 164: 623-624.
223. Plazas J, Portilla J, Boix V, Perez-Mateo M. Sporobolomyces salmonicolor lymphadenitis in an AIDS patient. Pathogen or passenger? AIDS 1994; 8: 387-388.
224. McNicholas S, McDermott H, Power L et al. Sporobolomyces roseus in the cerebrospinal fluid of an immunocompetent patient - to treat or not to treat? J Med Microbiol 2012; 61: 295-296.
225. Sharma V, Shankar J, Kotamarthi V. Endogeneous endophthalmitis caused by Sporobolomyces salmonicolor. Eye 2005; 20: 945-946.
226. Bergman AG, Kauffman CA. Dermatitis due to Sporobolomyces infection. Arch Dermatol 1984; 120: 1059-1060.
227. Cockcroft DW, Berscheid BA, Ramshaw IA, Dolovich J. Sporobolomyces: a possible cause of extrinsic allergic alveolitis. J Allergy Clin Immunol 1983; 72: 305-309.
228. Seuri M, Husman K, Kinnunen H et al. An outbreak of respiratory diseases among workers at a water-damaged building - a case report. Indoor Air 2000; 10: 138-145.
229. Bross JE, Manning P, Kacian D, Talbot GH. Pseudomeningitis caused by Sporobolomyces salmonicolor. Am J Infect Control 1986; 14: 220-223.
230. Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109, 496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 1998; 36: 198-202.
231. Colombo AL, Padovan AC, Chaves GM. Current knowledge of Trichosporon spp. and Trichosporonosis. Clin Microbiol Rev 2011; 24: 682-700.
232. Ruan SY, Chien JY, Hsueh PR. Invasive trichosporonosis caused by Trichosporon asahii and other unusual Trichosporon species at a medical center in Taiwan. Clin Infect Dis 2009; 49: e11-e17.
233. Fournier S, Pavageau W, Feuillhade M et al. Use of voriconazole to successfully treat disseminated Trichosporon asahii infection in a patient with acute myeloid leukaemia. Eur J Clin Microbiol Infect Dis 2002; 21: 892-896.
234. Wynne SM, Kwon-Chung KJ, Shea YR et al. Invasive infection with Trichosporon inkin in 2 siblings with chronic granulomatous disease. J Allergy Clin Immunol 2004; 114: 1418-1424.
235. Hickey PW, Sutton DA, Fothergill AW et al. Trichosporon mycotoxinivorans, a novel respiratory pathogen in patients with cystic fibrosis. J Clin Microbiol 2009; 47: 3091-3097.
236. Kontoyiannis DP, Torres HA, Chagua M et al. Trichosporonosis in a tertiary care cancer center: risk factors, changing spectrum and determinants of outcome. Scand J Infect Dis 2004; 36: 564-569.
237. Matsue K, Uryu H, Koseki M, Asada N, Takeuchi M. Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin. Clin Infect Dis 2006; 42: 753-757.
238. Suzuki K, Nakase K, Kyo T et al. Fatal Trichosporon fungemia in patients with hematologic malignancies. Eur J Haematol 2010; 84: 441-447.
239. Bayramoglu G, Sonmez M, Tosun I, Aydin K, Aydin F. Breakthrough Trichosporon asahii fungemia in neutropenic patient with acute leukemia while receiving caspofungin. Infection 2008; 36: 68-70.
240. Pagano L, Caira M, Candoni A et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006; 91: 1068-1075.
241. Walsh TJ, Groll A, Hiemenz J, Fleming R, Roilides E, Anaissie E. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect 2004; 10(Suppl 1): 48-66.
242. Panagopoulou P, Evdoridou J, Bibashi E et al. Trichosporon asahii: an unusual cause of invasive infection in neonates. Pediatr Infect Dis J 2002; 21: 169-170.
243. Vashishtha VM, Mittal A, Garg A. A fatal outbreak of Trichosporon asahii sepsis in a neonatal intensive care unit. Indian Pediatr 2012; 49: 745-747.
244. Moreno S, Buzon L, Sanchez-Sousa A. Trichosporon capitatum fungemia and intravenous drug abuse. Rev Infect Dis 1987; 9: 1202-1203.
245. Liao Y, Hartmann T, Ao JH, Yang RY. Serum glucuronoxylomannan may be more appropriate for the diagnosis and therapeutic monitoring of Trichosporon fungemia than serum β-d-glucan. Int J Infect Dis 2012; 16: e638.
246. McManus EJ, Bozdech MJ, Jones JM. Role of the latex agglutination test for cryptococcal antigen in diagnosing disseminated infections with Trichosporon beigelii. J Infect Dis 1985; 151: 1167-1169.
247. McManus EJ, Jones JM. Detection of a Trichosporon beigelii antigen cross-reactive with Cryptococcus neoformans capsular polysaccharide in serum from a patient with disseminated Trichosporon infection. J Clin Microbiol 1985; 21: 681-685.
248. Campbell CK, Payne AL, Teall AJ, Brownell A, Mackenzie DW. Cryptococcal latex antigen test positive in patient with Trichosporon beigelii infection. Lancet 1985; 2: 43-44.
249. Melcher GP, Reed KD, Rinaldi MG, Lee JW, Pizzo PA, Walsh TJ. Demonstration of a cell wall antigen cross-reacting with cryptococcal polysaccharide in experimental disseminated trichosporonosis. J Clin Microbiol 1991; 29: 192-196.
250. Nakase K, Suzuki K, Kyo T, Kohara T, Sugawara Y, Katayama N. Is elevation of the serum β-d-glucan level a paradoxical sign for Trichosporon fungemia in patients with hematologic disorders? Int J Infect Dis 2012; 16: e2-e4.
251. Kushima H, Ishii H, Komiya K, Tokimatsu I, Kadota JI. Prognostic significance of serum β-d-glucan levels in 78 patients with Trichosporon fungemia. Int J Infect Dis 2013; 17: e134-e135.
252. Shinozaki M, Okubo Y, Sasai D et al. Development of a peptide nucleic acid probe to Trichosporon species and identification of trichosporonosis by use of in situ hybridization in formalin-fixed and paraffin-embedded (FFPE) sections. J Clin Microbiol 2013; 51: 295-298.
253. Hosoki K, Iwamoto S, Kumamoto T, Azuma E, Komada Y. Early detection of breakthrough trichosporonosis by serum PCR in a cord blood transplant recipient being prophylactically treated with voriconazole. J Pediatr Hematol Oncol 2008; 30: 917-919.
254. Spiess B, Seifarth W, Hummel M et al. DNA microarray-based detection and identification of fungal pathogens in clinical samples from neutropenic patients. J Clin Microbiol 2007; 45: 3743-3753.
255. Nagai H, Yamakami Y, Hashimoto A, Tokimatsu I, Nasu M. PCR detection of DNA specific forTrichosporon species in serum of patients with disseminated trichosporonosis. J Clin Microbiol 1999; 37: 694-699.
256. Araujo RM, Alastruey-Izquierdo A, Gomez-Lopez A, Rodriguez-Tudela JL, Cuenca-Estrella M. Molecular identification and susceptibility testing of Trichosporon isolates from a Brazilian hospital. Rev Iberoam Micol 2008; 25: 221-225.
257. Rodriguez-Tudela JL, Diaz-Guerra TM, Mellado E et al. Susceptibility patterns and molecular identification of Trichosporon species. Antimicrob Agents Chemother 2005; 49: 4026-4034.
258. Sugita T, Nakajima M, Ikeda R, Matsushima T, Shinoda T. Sequence analysis of the ribosomal DNA intergenic spacer 1 regions of Trichosporon species. J Clin Microbiol 2002; 40: 1826-1830.
259. Kolecka A, Khayhan K, Groenewald M et al. MALDI-TOF MS identification of medically relevant species of arthroconidial yeasts. J Clin Microbiol 2013; 51: 2491-2500.
260. Asada N, Uryu H, Koseki M, Takeuchi M, Komatsu M, Matsue K. Successful treatment of breakthrough Trichosporon asahii fungemia with voriconazole in a patient with acute myeloid leukemia. Clin Infect Dis 2006; 43: e39-e41.
261. Serena C, Gilgado F, Marine M, Pastor FJ, Guarro J. Efficacy of voriconazole in a guinea pig model of invasive trichosporonosis. Antimicrob Agents Chemother 2006; 50: 2240-2243.
262. Rodriguez-Tudela JL, Gomez-Lopez A, Alastruey-Izquierdo A, Mellado E, Bernal-Martinez L, Cuenca-Estrella M. Genotype distribution of clinical isolates of Trichosporon asahii based on sequencing of intergenic spacer 1. Diagn Microbiol Infect Dis 2007; 58: 435-440.
263. Chagas-Neto TC, Chaves GM, Melo AS, Colombo AL. Bloodstream infections due to Trichosporon spp.: species distribution, Trichosporon asahii genotypes determined on the basis of ribosomal DNA intergenic spacer 1 sequencing, and antifungal susceptibility testing. J Clin Microbiol 2009; 47: 1074-1081.
264. Taj-Aldeen SJ, Al-Ansari N, El Shafei S et al. Molecular identification and susceptibility of Trichosporon species isolated from clinical specimens in Qatar: isolation of Trichosporon dohaense Taj-Aldeen, Meis & Boekhout sp. nov. J Clin Microbiol 2009; 47: 1791-1799.
265. Hoy J, Hsu KC, Rolston K, Hopfer RL, Luna M, Bodey GP. Trichosporon beigelii infection: a review. Rev Infect Dis 1986; 8: 959-967.
266. Walsh TJ, Melcher GP, Rinaldi MG et al. Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol 1990; 28: 1616-1622.
267. Marty FM, Barouch DH, Coakley EP, Baden LR. Disseminated trichosporonosis caused by Trichosporon loubieri. J Clin Microbiol 2003; 41: 5317-5320.
268. Tokimatsu I, Kushima H, Hashinaga K et al. The prophylactic effectiveness of various antifungal agents against the progression of trichosporonosis fungemia to disseminated disease in a neutropenic mouse model. Int J Antimicrob Agents 2007; 29: 84-88.
269. Hosokawa K, Yamazaki H, Mochizuki K et al. Successful treatment of Trichosporon fungemia in a patient with refractory acute myeloid leukemia using voriconazole combined with liposomal amphotericin B. Transpl Infect Dis 2012; 14: 184-187.
270. Gabriel F, Noel T, Accoceberry I. Fatal invasive trichosporonosis due to Trichosporon loubieri in a patient with T-lymphoblastic lymphoma. Med Mycol 2010; 49: 306-310.
271. Antachopoulos C, Papakonstantinou E, Dotis J et al. Fungemia due to Trichosporon asahii in a neutropenic child refractory to amphotericin B: clearance with voriconazole. J Pediatr Hematol Oncol 2005; 27: 283-285.
272. Groll AH, Giri N, Petraitis V et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 2000; 182: 274-282.
273. Hamill RJ, Sobel JD, El-Sadr W et al. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety. Clin Infect Dis 2010; 51: 225-232.